Clinical Trial Update: Evaluating the Efficacy and Safety of Oral Ranirestat (40 and 80 mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy [Phase 2, Phase 3]

View source ↗

Summary

The update covers results from Phase 2 and Phase 3 trials evaluating oral ranirestat at 40 mg and 80 mg for diabetic sensorimotor polyneuropathy, with the studi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Sensorimotor Polyneuropathy

Drugs mentioned

• Ranirestat (ranirestat)

Snippet

Sponsor: Eisai Inc. | Conditions: Mild to Moderate Diabetic Sensorimotor Polyneuropathy | Phase 2, Phase 3 | Status: COMPLETED